Verve Therapeutics EBIT

The latest EBIT for VERV is $-210M as of March 2025. That compares with $-220M in the prior-year period — up 5.8% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Verve Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VERV's EBIT moved from $-220M to $-210M — a 5.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Verve Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, VERV currently prints $-210M for EBIT, while the sector average sits near $23B. That is roughly 100.9% below the sector mean. Large gaps often invite a closer look at Verve Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-210M for VERV is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting VERV's EBIT ($-210M), review year-over-year change from $-220M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.